AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 42 min read$BCRX

BioCryst: Q3 Earnings Snapshot

BioCryst Pharmaceuticals reported Q3 earnings of $37.9M, or 14 cents per share, exceeding expectations. Revenue was $180.3M, also above forecasts. The company expects full-year revenue between $715M and $730M. Shares are up 10% YTD and 25% over the past year.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 12:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BioCryst: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BCRXBullishMed
01

Why it matters

The earnings beat suggests stronger demand for its pipeline products, potentially improving cash flow and funding for upcoming trials.

02

Market read

First-report earnings beat with raised guidance provides a fresh catalyst for BCRX, likely prompting short-term buying interest.

03

What to watch

Potential upcoming regulatory or clinical trial outcomes could offset earnings momentum.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

BioCryst Pharmaceuticals Inc. (BCRX) is a specialty biopharmaceutical company focused on rare disease treatments.

Company-level read

Ticker impact

$BCRXBullishHigh confidence
Context

BioCryst reported Q3 earnings of $37.9M, EPS 14c beating estimates of 10c and revenue $180.3M beating $166.4M forecasts.

Expected impact

upward pressure as the market prices in the earnings beat and raised full-year revenue guidance.

Evidence & confidence

Both earnings per share and revenue exceeded analyst expectations, and guidance is raised, supporting a bullish move.

Market effects

Sector

Positive for biotech sector as earnings beat may boost confidence in similar small-cap drugmakers.

Regional

Limited to US biotech investors.

Global

Minor global impact, primarily US-listed biotech investors.

Counterpoint

What could challenge this read

If guidance falls short of expectations later, the rally could be short-lived.

Key entities

  • company
    BioCryst Pharmaceuticals Inc.

    Issuer of the earnings report.

Read at source← All news

StoryBioCryst posts Q3 earnings beat and raises full-year revenue outlook

Also covered by

1 outlet

Related articles

NOV 4
$BCRXMedAI 8/10

BioCryst (BCRX) Q3 2026 Earnings Call Transcript

BioCryst (BCRX) reported Q3 2026 earnings, highlighting growth in ORLADEYO pellet usage among children and a transition to CareMed as their sole pharmacy partner. The company expects to announce top-line data for navenibart in Q3 2027 and is on track to share early clinical data for BCX1771 by year-end. Revenue was $174.8 million, with ORLADEYO revenue increasing 20% year-over-year. The company anticipates continued revenue growth and cost savings in 2027.

finance.yahoo.com7 min
NOV 4
$BCRXHighAI 8/10

BioCryst Q3 2026 slides: HAE portfolio drives 70% profit jump

BioCryst Pharmaceuticals (BCRX) reported Q3 2026 non-GAAP operating profit of $87M, up 70% YoY, driven by ORLADEYO revenue of $175M. The company raised full-year 2026 revenue guidance to $715M-$730M. ORLADEYO showed 91% reduction in monthly attack rate for HAE patients. Navenibart, a potential second HAE treatment, is in Phase 3 trials with data expected in Q3 2027. BioCryst also highlighted its pipeline, including BCX17725 for Netherton syndrome.

investing.com3 min
NOV 4
$BCRXHighAI 8/10

BioCryst Pharmaceuticals Q3 Earnings Call Highlights

BioCryst Pharmaceuticals reported Q3 non-GAAP net income of $71M, up from last year. The company launched ORLADEYO pellets for children and plans to introduce a 150-mg pellet formulation. Pediatric uptake is ahead of expectations. BioCryst maintained 2026 ORLADEYO revenue guidance of $625M-$645M but raised total revenue guidance to $715M-$730M. The company is also progressing with its navenibart trial for HAE and BCX17725 study for Netherton syndrome.

finance.yahoo.com2 min
NOV 4
$BCRXHigh

BioCryst Reports Third Quarter 2026 Financial Results

BIOCRYST PHARMACEUTICALS INC (BCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioCryst Reports Third Quarter 2026 Financial Results — Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenu

SEC EDGAR 8-K2 min
OCT 22
$BCRXHighAI 9/10

FDA Approves Berotralstat Oral Pellets for Adults, Adolescents With HAE

BioCryst Pharmaceuticals announced FDA approval of a 150 mg oral pellet formulation of berotralstat (Orladeyo) for HAE prophylaxis in patients aged 12+. The approval adds a second dosage form, following prior approvals for capsules and pediatric pellets. BioCryst reports berotralstat is the only targeted oral prophylactic therapy for HAE patients aged 2+.

hcplive.com2 min